Searching for your content…
from 8 AM – 10 PM ET
An increase in the number of surgeries, advancement in the current and emerging treatment options, and rise in the patient population proffer the impetus to Postoperative Pain Market Growth in the 7MM.
News provided by
Jun 30, 2021, 12:30 ET
Share this article
LAS VEGAS, June 30, 2021 /PRNewswire/ — DelveInsight’s "Postoperative Pain Market" report provides a thorough comprehension of the Postoperative Pain historical and forecasted epidemiology and the Postoperative Pain market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Postoperative Pain market report also proffers an analysis of the current Postoperative Pain treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
Some of the necessary takeaways from the Postoperative Pain Market Research Report
For further information on Market Impact by Therapies, visit: Postoperative Pain Drugs Market Analysis
Postoperative Pain is defined as a condition of tissue injury together with muscle spasms after surgery. Postoperative Pain patients can be sub-segmented based on severity as mild, moderate, and severe.
As per DelveInsight’s estimates, the Postoperative Pain incident cases were around 66,426,881 cases in the 7MM in 2020. Moreover, the United States has the highest percentage of the Postoperative Pain patient pool among these countries.
The Postoperative Pain Market Analysis Report provides historical as well as forecasted epidemiological analysis segmented into:
Get a complete epidemiological segmentation @ Postoperative Pain Epidemiological Analysis
Postoperative Pain Treatment Market
Postoperative Pain management aims to decline pain intensity, increase patient comfort, and improve postoperative outcomes. Pain-relieving analgesics include opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), and acetaminophen.
Opioids are a large group of pain-relieving drugs that are utilized for alleviating pain in postoperative cases. These drugs majorly comprise fentanyl, hydromorphone, morphine, oxycodone, oxymorphone, and tramadol. In addition, the approved opioids include Zalviso, Olinvyk (Olinvo), Dzuveo/Dsuvia, Nucynta, DepoDur, and others. However, opioids have many dose-limiting side effects that range from bothersome to life-threatening.
Postoperative Pain Treatment Market Forecast and Recent Approvals
Recently, in February 2021, FDA approved Posimir, a potential drug that is awaiting launch. Similar to Posimir, bupivacaine is the active ingredient in Pacira Biosciences’ Exparel, also indicated for postsurgical pain relief. Being the clear market leader in branded post-surgical local anesthesia, Exparel (bupivacaine liposome injectable suspension) has generated impressive sales after its approval (effectively from the US). Posimir has been approved with limited labels, and thus, it is slightly evident that it might not give a head-to-head competition to Exparel. In addition, Xaracoll is an implant that is a unique, non-injectable, drug-device combination in the form of a fully bioresorbable collagen implant containing bupivacaine hydrochloride, providing postsurgical pain relief through the delivery of bupivacaine, a local anesthetic, at the surgical site. Although it is presently approved in the US, weak efficacy data might prevent it from becoming a substantial competitor in the pain management market.
In 2018, local anesthetics grew around 20% in value, while opioids declined. Thus, it can be anticipated that local anesthetic demand will be very high in the Postoperative Pain market, and future, upcoming therapies can hold a tight market. Besides, the potential market for an effective long-acting local anesthetic working 72-h is enormous.
Although Posimir and Xaracoll might not be significant threats to Exparel’s market leadership, Heron Therapeutics’ Zynrelef is ripe to compete with Exparel. Formerly known as HTX-011, it is one such drug with 72 h anesthetic action that is initially targeting many million procedures, including hospital inpatient, hospital outpatient, and ambulatory surgical centers (ASCs). The drug could be a threat to Pacira Biosciences’ Exparel as recently the HTX-011 received a nod from US FDA, and soon it will be launched in the US market.
While Zynrelef has received marketing approvals in the EU, Exparel has been in the Postoperative Pain market for more than a decade and has the edge over others. Despite that, Heron’s candidate might stand out and become a direct competitor to Exparel in the future; several factors, including multiple advantages shown in its safety and efficacy data, might play a role. The drawbacks could be a limited use, which is only at the incision site and not in peripheral nerve blocks. HTX-011 has been tested in surgical settings and requires a surgeon to administer the drug, whereas Exparel has been adopted in expanding ASC settings. The popularity and use will depend on the product’s cost after approval and availability all over. Nevertheless, HTX-011 approval has been full of controversy. Still, DelveInsight anticipates that it will cover a massive Postoperative Pain market by 2030.
HTX-011 will face stiff competition in the US and EU-5: DelveInsight’s Analyst Views. In the US, HTX-011 will compete with Marcaine (bupivacaine hydrochloride injection, solution, marketed by Pfizer Inc.) and generic forms of bupivacaine; Naropin (ropivacaine, marketed by Fresenius Kabi USA, LLC) and its generic forms; Exparel (bupivacaine liposome injectable suspension, marketed by Pacira BioSciences, Inc.); Xaracoll (bupivacaine HCl implant, marketed by Innocoll Pharmaceuticals Limited); Posimir (marketed by Durect Corporation); Anjeso (meloxicam injection, marketed by Baudax Bio, Inc.); Ofirmev (acetaminophen injection, marketed by Mallinckrodt Pharmaceuticals) and generic forms of IV acetaminophen; and potentially other products in development for Postoperative Pain management that reach the US market. Similarly, in EU-5, numerous generic local anesthetics and other nonopioids for postoperative pain management are available in the EU, and other products in development for postoperative pain management may also reach the EU market. For example, in November 2020, the EC granted marketing authorization for Exparel (bupivacaine liposome injectable suspension, marketed by Pacira BioSciences, Inc. in the US) for postsurgical analgesia. Pacira BioSciences, Inc. has indicated that it expects launching Exparel in the EU in the second half of 2021.
If approved, Cara Therapeutics IV CR845 would be competing within the overall acute postoperative pain market. However, the company expects to compete primarily with injectable mu-opioid analgesics, such as morphine, fentanyl, and hydromorphone.
Scope of the Postoperative Pain Market Insight Report
Request for a Webex demo of the report @ Postoperative Pain Therapeutics Market
Table of Contents
Postoperative Pain Report Introduction
Postoperative Pain Market Overview at a Glance
Postoperative Pain Market: Future Perspective
Executive Summary of Postoperative Pain
Postoperative Pain Disease Background and Overview
Postoperative Pain Epidemiology and Patient Population
The United States
The United Kingdom
Postoperative Pain Patient Journey
Postoperative Pain Marketed Drugs
Enanplus/Takudex (Dexketoprofen/Tramadol): Menarini Group/Guidotti Farma
Dsuvia/Dzuveo (Sufentanil): AcelRx Pharmaceuticals
Zalviso: AcelRx Pharmaceuticals
Olinvyk (Olinvo) (oliceridine): Trevena, Inc.
Zynrelef (HTX-011): Heron Therapeutics
Xaracoll: Innocoll Pharmaceuticals
Posimir (bupivacaine solution): DURECT Corporation
Exparel: Pacira Pharmaceuticals
Anjeso: Baudax Bio
Prolensa (bromfenac ophthalmic solution) 0.07%: Bausch & Lomb
Dextenza: Ocular Therapeutix
Inveltys: Kala Pharmaceuticals, Inc.
Penthrox: Medical Developments International Ltd (MVP)
Lotemax SM (loteprednol etabonate ophthalmic gel): Bausch & Lomb
Maxigesic: Hyloris Pharmaceuticals/AFT Pharmaceuticals
Postoperative Pain Emerging Therapies
CR845/Difelikefalin: Cara Therapeutics
VVZ-149 Injections: Vivozon, Inc.
Tramadol IV: Avenue Therapeutics, Inc.
F14 (sustained-release celecoxib)/mdc-CWM (Celecoxib): Arthritis Innovation Corporation/MedinCell
Nefopam hydrochloride and paracetamol: Unither Pharmaceuticals
Co-crystal E-58425 (Tramadol/Celecoxib): Esteve Pharmaceuticals
APP13007: Formosa Pharmaceuticals
NTM-001 (Ketorolac Pre-Mixed Bag): Neumentum Pharmaceuticals
ACP-044: Acadia Pharmaceuticals Inc.
NVK-009 (Pregabalin and Acetaminophen): Nevakar, Inc.
TLC590: Taiwan Liposome Company (TLC)
MR-107A-01: Viatris Inc. (formerly known as Mylan Inc.)
TPU-006 (Dexmedetomidine Transdermal System (DMTS)): Teikoku Pharma USA, Inc.
SAF312: Novartis Pharmaceuticals
PRF110: PainReform LTD
Vocacapsaicin (CA-008): Concentric Analgesics
Nepafenac PPDS/Nepafenac Evolute: Mati Therapeutics Inc.
Postoperative Pain: 7MM Market Analysis
The United States Postoperative Pain Market Size
EU-5 Postoperative Pain Market Size
Germany Market Size
France Market Size
Italy Market Size
Spain Market Size
The United Kingdom Market Size
Japan Postoperative Pain Market Size
Postoperative Pain Market Drivers
Postoperative Pain Market Barriers
Postoperative Pain SWOT Analysis
Postoperative Pain Unmet Needs
Reimbursement and Postoperative Pain Market Access
Browse full report with detailed TOC with charts, figures, tables @ Postoperative Pain Diagnostics Market Report
View Related Reports
Postoperative Pain Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Postoperative Pain. Key companies involved in developing Postoperative Pain therapies are Heron Therapeutics, Cara Therapeutics, Endo Pharmaceuticals, Mylan, Concentric Analgesics, Camurus, PainReform, Layerbio, Jiangsu HengRui Medicine, Polypid, Pharmaleads, Layerbio, Neumentum, and others.
DelveInsight’s Chronic Pain Market Insights, Epidemiology and Market Forecast – 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. The market players are Pfizer, Eli Lilly and Company, Regeneron, Teva Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, ABBVie, Stayble Therapeutics, Aptinyx, Lateral Pharma, Samumed, Sorrento Therapeutics, Ampio Pharmaceuticals, and others that are developing therapies for Chronic Pain patients.
DelveInsight’s Acute Ocular Pain Market Insights, Epidemiology and Market Forecast – 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. Key players involved in the Acute Ocular Pain pipeline are Ocular Therapeutix, Kala Pharmaceuticals, Sun Pharmaceutical, Bausch & Lomb, Formosa Pharmaceuticals, Aldeyra Therapeutics, Sylentis, and others.
DelveInsight’s ‘Central Venous Catheters Market Insights, Competitive Landscape and Market Forecast-2026’ report delivers an in-depth understanding of Central Venous Catheters.
DelveInsight’s Keloid – Market Insights, Epidemiology and Market Forecast – 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
"Oncolytic Virus Cancer Therapy" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. CG Oncology, Oncolytics Biotech, Astellas Pharma, DNAtrix, Nouscom, ImmVira Pharma, Targovax, Istari Oncology, SillaJen Biotherapeutics, and others are a few companies that will be drifting Oncolytic Virus Cancer Therapy treatment scenario.
Capnography Devices Market Insights, Competitive Landscape and Market Forecast-2026 report delivers an in-depth understanding of Capnography Devices and the historical and forecasted epidemiology. Some notable companies such as Smiths Medical, Dragerwerk AG & Co. KGaA., Welch Allyn, Inc., Masimo Corporation, Philips Healthcare, Medtronic, Inc., Nonin Medical, Nihon Kohden Corporation, and others are changing Capnography Devices Market dynamics.
Cardiac Resynchronization Therapy Market Insights, Competitive Landscape and Market Forecast-2026 report delivers an in-depth understanding of Cardiac Resynchronization Therapy. Boston Scientific Corporation, Medtronic, Medico S.p. A, Microport Scientific Corporation, Biotronik, EBR Systems, Inc, and Abbott are pulling up the Cardiac Resynchronization Therapy market.
Browse Blog Posts
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Business Consulting Services with a credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.
SOURCE DelveInsight Business Research, LLP
Cision Distribution 888-776-0942
from 8 AM – 9 PM ET
Postoperative Pain Market to Rising Steadily at a 7.93% CAGR Owing to Growing Number of Surgeries, During the Study Period [2018-2030], Says DelveInsight – PR Newswire
Searching for your content…